Amneal Launches Bexarotene Gel, 1%
Amneal Pharmaceutical is now shipping Bexarotene Gel, 1%, an AB-rated generic equivalent to Targretin®. The Amneal product is sold in a carton containing one 60 gram aluminum tube. The gel is a clear, colorless gelled solution with a homogenous consistency.
Approved on April 27 of this year as an Abbreviated New Drug Application (ANDA) with CGT exclusivity by the US FDA, the Ameal product is the first true generic equivalent for Targretin® currently on the market.
According to IQVIA®, U.S. annual sales for Bexarotene Gel, 1%, for the 12 months ended April 2022 were $21,804,343.
Amneal Bexarotene Gel, 1% is available through wholesalers and distributors as well as directly to the trade.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.
The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit www.amneal.com.